Italia markets open in 3 hours 30 minutes

Vaccinex, Inc. (VCNX)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,8400-0,1500 (-3,01%)
Alla chiusura: 04:00PM EDT
4,6400 -0,20 (-4,13%)
Dopo ore: 07:36PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,9900
Aperto5,0200
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno4,8400 - 5,0200
Intervallo di 52 settimane4,7600 - 100,8000
Volume5.827
Media Volume13.221
Capitalizzazione7,668M
Beta (5 anni mensile)0,70
Rapporto PE (ttm)N/D
EPS (ttm)-43,6800
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Vaccinex Announces Pricing of $9.6 Million Public Offering

    ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company’s Board of Direct

  • GlobeNewswire

    Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

    Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells Successfully applied in proof-of-concept evaluation by OmniAb to select antibodies against ion channel and chemokine receptor proteins in transgenic animals ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology

  • GlobeNewswire

    Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

    Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present data